Total Payments
$40,438
2024 Payments
$1,832
Companies
69
Transactions
900
Medicare Patients
803
Medicare Billing
$258,252
Payment Breakdown by Category
Food & Beverage$18,938 (46.8%)
Consulting$13,140 (32.5%)
Travel$3,657 (9.0%)
Education$2,382 (5.9%)
Gifts$1,641 (4.1%)
Other$681.53 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,938 | 817 | 46.8% |
| Consulting Fee | $13,140 | 12 | 32.5% |
| Travel and Lodging | $3,657 | 9 | 9.0% |
| Education | $2,382 | 37 | 5.9% |
| Gift | $1,641 | 18 | 4.1% |
| Long term medical supply or device loan | $681.53 | 7 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $9,389 | 87 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $5,197 | 45 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $4,706 | 73 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,175 | 118 | $0 (2023) |
| Celgene Corporation | $1,743 | 31 | $0 (2024) |
| Foundation Medicine, Inc. | $1,600 | 7 | $0 (2020) |
| PFIZER INC. | $975.48 | 61 | $0 (2024) |
| Seagen Inc. | $955.15 | 33 | $0 (2023) |
| Lilly USA, LLC | $948.69 | 39 | $0 (2024) |
| Incyte Corporation | $854.78 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,832 | 49 | AstraZeneca Pharmaceuticals LP ($618.49) |
| 2023 | $2,968 | 94 | Novartis Pharmaceuticals Corporation ($521.54) |
| 2022 | $4,294 | 116 | E.R. Squibb & Sons, L.L.C. ($1,321) |
| 2021 | $3,140 | 117 | Janssen Biotech, Inc. ($412.25) |
| 2020 | $3,357 | 83 | Celgene Corporation ($1,178) |
| 2019 | $13,145 | 136 | Janssen Biotech, Inc. ($7,533) |
| 2018 | $3,147 | 141 | Novartis Pharmaceuticals Corporation ($453.00) |
| 2017 | $8,556 | 164 | E.R. Squibb & Sons, L.L.C. ($3,330) |
All Payment Transactions
900 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $9.08 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.07 | General |
| Category: Hematology | ||||||
| 10/02/2024 | Janssen Biotech, Inc. | AKEEGA (Drug), ERLEADA, BALVERSA | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $31.26 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $34.94 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Oncology | ||||||
| 08/15/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $32.79 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: ONCOLOGY | ||||||
| 08/14/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Oncology | ||||||
| 08/08/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $25.45 | General |
| Category: Oncology | ||||||
| 07/15/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $27.14 | General |
| Category: Oncology | ||||||
| 07/01/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.02 | General |
| Category: Hematology | ||||||
| 06/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $32.11 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: Oncology | ||||||
| 05/01/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.23 | General |
| Category: Hematology/Oncology | ||||||
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | — | Education | In-kind items and services | $99.94 | General |
| 04/27/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: Oncology | ||||||
| 04/22/2024 | Janssen Biotech, Inc. | BALVERSA (Drug), AKEEGA, ERLEADA | Food and Beverage | In-kind items and services | $38.05 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.99 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 160 | 484 | $121,545 | $52,441 |
| 2022 | 5 | 202 | 625 | $152,737 | $67,242 |
| 2021 | 5 | 217 | 701 | $161,136 | $74,596 |
| 2020 | 4 | 224 | 737 | $113,885 | $63,972 |
Total Patients
803
Total Services
2,547
Medicare Billing
$258,252
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 252 | $59,220 | $25,884 | 43.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 47 | 140 | $45,500 | $21,073 | 46.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 43 | $13,975 | $4,242 | 30.4% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 12 | 49 | $2,850 | $1,242 | 43.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 111 | 375 | $88,125 | $38,134 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 158 | $51,200 | $24,611 | 48.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 25 | $8,475 | $2,203 | 26.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 34 | $4,475 | $2,198 | 49.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 15 | 33 | $462.00 | $95.07 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 118 | 420 | $91,835 | $41,730 | 45.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 60 | 198 | $60,025 | $28,943 | 48.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 12 | 12 | $4,500 | $1,965 | 43.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 30 | $4,020 | $1,855 | 46.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 15 | 41 | $756.00 | $103.75 | 13.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 129 | 465 | $71,960 | $38,017 | 52.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 55 | 193 | $33,775 | $22,970 | 68.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 25 | 48 | $7,170 | $2,893 | 40.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 15 | 31 | $980.00 | $92.46 | 9.4% |
About Dr. Andrea Edwards, MD
Dr. Andrea Edwards, MD is a Medical Oncology healthcare provider based in Santa Cruz, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255341962.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrea Edwards, MD has received a total of $40,438 in payments from pharmaceutical and medical device companies, with $1,832 received in 2024. These payments were reported across 900 transactions from 69 companies. The most common payment nature is "Food and Beverage" ($18,938).
As a Medicare-enrolled provider, Edwards has provided services to 803 Medicare beneficiaries, totaling 2,547 services with total Medicare billing of $258,252. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Santa Cruz, CA
- Active Since 08/08/2006
- Last Updated 07/18/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1255341962
Products in Payments
- Balversa (Drug) $4,699
- OPDIVO (Biological) $3,673
- KISQALI (Drug) $2,527
- FOUNDATIONACT (Device) $1,315
- TAGRISSO (Drug) $814.38
- ERLEADA (Drug) $760.64
- ADCETRIS (Biological) $734.75
- KEYTRUDA (Biological) $627.18
- IMFINZI (Biological) $600.02
- IBRANCE (Drug) $553.38
- DARZALEX (Biological) $477.06
- IMBRUVICA (Drug) $439.57
- JEVTANA (Drug) $427.49
- NINLARO (Drug) $381.88
- TASIGNA (Drug) $375.13
- VENCLEXTA (Drug) $373.36
- CALQUENCE (Drug) $370.01
- Lenvima (Drug) $342.97
- MEKINIST (Drug) $338.20
- FOTIVDA (Drug) $329.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.